AR116464A1 - Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 - Google Patents

Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6

Info

Publication number
AR116464A1
AR116464A1 ARP190102673A ARP190102673A AR116464A1 AR 116464 A1 AR116464 A1 AR 116464A1 AR P190102673 A ARP190102673 A AR P190102673A AR P190102673 A ARP190102673 A AR P190102673A AR 116464 A1 AR116464 A1 AR 116464A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
independently
group
haloc1
Prior art date
Application number
ARP190102673A
Other languages
English (en)
Inventor
Huixian Wu
Rayomand Jal Unwalla
John Isidro Trujillo
Atli Thorarensen
Daniel Copley Schmitt
Jr Ralph Pelton Robinson
Philippe Marcel Nuhant
Daniel Wei Kung
- Flick Andrew Christopher Shung
Mark Edward Schnute
James John Mousseau
Vincent Michael Lombardo
Brian Stephen Gerstenberger
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR116464A1 publication Critical patent/AR116464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos derivados de dioxociclobutenilamino-3-hidroxi-picolinamida N-sustituida como inhibidores de CCR6 y el uso de los mismos en el tratamiento de enfermedades inflamatorias tales como artritis reumatoidea. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) ó (2) o una sal o un hidrato de estos aceptables desde el punto de vista farmacéutico, en donde R¹ y R² son independientemente H, C₁₋₆ alquilo, o R¹ y R², junto con el átomo de nitrógeno al que están unidos forman un heterociclo de 4, 5 ó 6 miembros que contiene un heteroátomo N, y opcionalmente, 1 ó 2 heteroátomos adicionales seleccionados del grupo que consiste en O, N y S, en donde el heterociclo se sustituye opcionalmente con 1, 2 ó 3 grupos C₁₋₄ alquilo; R³ es H, C₁₋₆ alquilo, C₁₋₄ alquilcarbonilo, -C(=O)CH=CHCO₂H, -SO₂NH₂, -CH₂OC(=O)C₁₋₄ alquilo, -CH₂OP(=O)(OH)₂ o -C(=O)NRARB, en donde el C₁₋₄ alquilcarbonilo se sustituye opcionalmente con -CO₂H, o -NH₂, en donde -CH₂OC(=O)C₁₋₄ alquilo se sustituye opcionalmente con -NH₂, y en donde RA y RB son independientemente H o C₁₋₆ alquilo; A es un compuesto del grupo de fórmulas (3); R⁴ es H, C₁₋₄ alquilo, C₃₋₄ cicloalquilo, C₃₋₄ cicloalquilC₁₋₄ alquilo o haloC₁₋₄ alquilo; R⁵ y R⁶ son, independientemente, H, deuterio, C₂₋₄ alquenilo, C₁₋₄ alcoxi, C₁₋₄ alquilo, C₁₋₄ alquil-d₁₋₉, C₃₋₄ cicloalquilo, C₃₋₄ cicloalquilC₁₋₄ alquilo, ciano, halógeno, haloC₁₋₄ alcoxi, haloC₁₋₄ alquilo o hidroxiC₁₋₄ alquilo; B es un compuesto del grupo de fórmulas (4); R⁷ es -F, -CN, C₁₋₃ alquilo, C₁₋₃ alquil-d₁₋₇ o haloC₁₋₃ alquilo; R⁸, en cada caso, es independientemente deuterio, -F, -Cl, -Br o -l, o dos R⁸ unidos al mismo átomo de carbono forman un grupo C₃₋₅ cicloalquilo; n es 0, 1, 2, 3 ó 4; R⁹, en cada caso, es independientemente deuterio, -F, -Cl, -Br o -l, o dos R⁹ unidos al mismo átomo de carbono forman un grupo C₃₋₅ cicloalquilo; m es 1, 2, 3 ó 4; y X es O, S o NRC, en donde RC es H o C₁₋₄ alquilo.
ARP190102673A 2018-09-21 2019-09-20 Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 AR116464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734486P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
AR116464A1 true AR116464A1 (es) 2021-05-12

Family

ID=68051869

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102673A AR116464A1 (es) 2018-09-21 2019-09-20 Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6

Country Status (29)

Country Link
US (2) US10975065B2 (es)
EP (1) EP3852879A1 (es)
JP (1) JP6989729B2 (es)
KR (2) KR102615234B1 (es)
CN (2) CN116874466A (es)
AR (1) AR116464A1 (es)
AU (1) AU2019344107B2 (es)
BR (1) BR112021003956A2 (es)
CA (1) CA3055805A1 (es)
CL (1) CL2021000683A1 (es)
CO (1) CO2021003391A2 (es)
CR (1) CR20210146A (es)
CU (1) CU20210016A7 (es)
DO (1) DOP2021000045A (es)
EA (1) EA202190586A1 (es)
EC (1) ECSP21018584A (es)
GE (1) GEP20237476B (es)
IL (1) IL281634A (es)
MA (1) MA53643A (es)
MX (1) MX2021003318A (es)
NI (1) NI202100012A (es)
NZ (1) NZ773473A (es)
PE (1) PE20211070A1 (es)
PH (1) PH12021550554A1 (es)
SG (1) SG11202101827RA (es)
TW (1) TWI754172B (es)
UY (1) UY38379A (es)
WO (1) WO2020058869A1 (es)
ZA (1) ZA202101169B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190586A1 (ru) * 2018-09-21 2021-07-05 Пфайзер Инк. N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
US20230174514A1 (en) 2020-04-30 2023-06-08 Idorsia Pharmaceuticals Ltd Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
CA3235910A1 (en) 2021-10-26 2023-05-04 Oliver Allemann Ccr6 receptor modulators
CA3236396A1 (en) 2021-10-28 2023-05-04 Oliver Allemann Ccr6 receptor modulators

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
AU686896B2 (en) 1994-11-16 1998-02-12 American Home Products Corporation Diaminocyclobutene-3,4-diones
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
CN1990457A (zh) 2001-04-16 2007-07-04 先灵公司 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮
AU2003220384B2 (en) 2002-03-18 2007-05-10 Merck Sharp & Dohme Corp. Combination treatments for chemokine-mediated diseases
ATE422203T1 (de) * 2002-10-09 2009-02-15 Schering Corp Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
PT2010509E (pt) 2006-03-31 2014-12-12 Janssen Pharmaceutica Nv Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona como agentes de dilatação do canal de potássio
MX2008015004A (es) 2006-05-26 2008-12-05 Abbott Lab Inhibidores de cinasas de tipo polo.
RU2009103999A (ru) 2006-07-07 2010-08-20 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокиновых рецепторов
NZ580660A (en) 2007-04-30 2012-02-24 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
AU2008258588B2 (en) 2007-06-06 2011-11-10 Novartis Ag Anti -inflammatory substituted cyclobutenedione compounds
US20100249439A1 (en) 2007-07-05 2010-09-30 Vincenzo Liotta Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
JP5292400B2 (ja) 2007-07-24 2013-09-18 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体
CN101808991A (zh) 2007-07-24 2010-08-18 百时美施贵宝公司 作为趋化因子受体活性调节剂的哌啶基衍生物
EP2252327A2 (en) 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010131146A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
PT2473049T (pt) 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
MX2012005463A (es) 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
CN103827095A (zh) 2011-08-30 2014-05-28 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
US9458174B2 (en) 2012-05-23 2016-10-04 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
MX2015007936A (es) 2012-12-19 2016-03-11 Novartis Ag Inhibidores de autotaxina.
US9624180B2 (en) 2013-01-25 2017-04-18 Bristol-Myers Squibb Company Squaric derivatives for the treatment of hepatitis C
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
US10660909B2 (en) * 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EA202190586A1 (ru) * 2018-09-21 2021-07-05 Пфайзер Инк. N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6

Also Published As

Publication number Publication date
DOP2021000045A (es) 2021-04-30
BR112021003956A2 (pt) 2021-05-25
KR102615234B1 (ko) 2023-12-19
ECSP21018584A (es) 2021-04-29
CR20210146A (es) 2021-05-20
CU20210016A7 (es) 2021-10-12
CN116874466A (zh) 2023-10-13
NZ773473A (en) 2023-07-28
GEP20237476B (en) 2023-03-27
EP3852879A1 (en) 2021-07-28
KR20230175326A (ko) 2023-12-29
US20210206757A1 (en) 2021-07-08
MX2021003318A (es) 2021-05-14
TWI754172B (zh) 2022-02-01
CO2021003391A2 (es) 2021-04-08
EA202190586A1 (ru) 2021-07-05
AU2019344107B2 (en) 2022-09-15
AU2019344107A1 (en) 2021-04-08
ZA202101169B (en) 2022-07-27
PH12021550554A1 (en) 2022-02-21
US11708360B2 (en) 2023-07-25
CN112672791A (zh) 2021-04-16
CA3055805A1 (en) 2020-03-21
SG11202101827RA (en) 2021-04-29
JP6989729B2 (ja) 2022-01-05
US20200095239A1 (en) 2020-03-26
JP2021532166A (ja) 2021-11-25
MA53643A (fr) 2021-12-29
TW202024056A (zh) 2020-07-01
US10975065B2 (en) 2021-04-13
KR20210046717A (ko) 2021-04-28
UY38379A (es) 2020-04-30
CN112672791B (zh) 2023-10-03
CL2021000683A1 (es) 2021-10-15
NI202100012A (es) 2021-06-22
WO2020058869A1 (en) 2020-03-26
IL281634A (en) 2021-05-31
PE20211070A1 (es) 2021-06-09

Similar Documents

Publication Publication Date Title
AR116464A1 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR114949A1 (es) Compuesto de benzamida
AR108387A1 (es) Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
AR111279A1 (es) Derivados heterocíclicos útiles como inhibidores duales de atx / ca
AR110405A1 (es) Compuestos
AR088449A1 (es) Benzilindazoles sustituidos
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR100059A1 (es) Compuestos útiles como inmunomoduladores
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR090834A1 (es) Inhibidores de la agregacion plaquetaria
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR113929A1 (es) Compuestos heterocíclicos
AR066448A1 (es) Inhibidores macrociclicos de la replicacion del virus de hepatitis c, composicion farmaceutica, metodos de obtencion del compuesto y compuestos intermediarios
AR095423A1 (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR062011A1 (es) Derivados de diazol y sus composiciones como inhibidores de itpkb
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR094550A1 (es) Inhibidores de btk
AR095708A1 (es) Indazoles sustituidos con diaminoheteroarilo
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
AR062405A1 (es) Derivados de isoindol
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas